Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZBX - Genzyme Biosurgery -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (9)	4/9/2001 7:54:29 PM
From: Joan Osland Graffius	Read Replies (1) \| Respond to of 18

Spek, I also started accumulating GZBX. It will be interesting to see how long we have to hold to get a good profit on this investment. Mother will keep the children from going bankrupt which takes away some of the risk. I also started accumulating GZTC at these levels. Joan

To: Spekulatius who wrote (9)	1/12/2002 6:07:05 PM
From: Extra Pale	Read Replies (1) \| Respond to of 18

Doing some dd on gzbx today and noted that $20m payment to genz for neurocell program is going to be payed in cash now, rather than stock, as previously disclosed. Gzbx has approximately $41m in cash so a $20m payment seems significant. Why the cash vs stock payment? does genz not want stock? Is gzbx turning cash positive, with less need for cash? what am I missing? Genzyme Biosurgery Provides Business Update Snowden-Pencer, Canadian Manufacturing Plant Sold CAMBRIDGE, Mass., Nov 26, 2001 /PRNewswire via COMTEX/ -- Genzyme Biosurgery (snip) The division also announced new plans regarding the method and timing of a payment to Genzyme General in connection with the termination of the development of NeuroCell(TM)-PD for Parkinson's disease. Genzyme Biosurgery plans to refund Genzyme General $20 million in the first quarter of 2002 using cash, rather than designated shares as previously announced. (snip)